The Journal of Immunology, Vol 140, Issue 3 713-716, Copyright © 1988 by American Association of Immunologists

ARTICLES

Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells

NL Carteron, D Wofsy and WE Seaman
Immunology/Arthritis Section, Veterans Administration Medical Center, San Francisco, CA 94121.

Treatment of mice with mAb to L3T4 profoundly depletes T helper cells. This treatment inhibits humoral and cellular immunity, retards autoimmunity, and permits the induction of Ag-specific tolerance. Treatment of BALB/c mice with F(ab')2 anti-L3T4 inhibits humoral immunity without depleting L3T4+ cells, which is evidence that mAb to L3T4 may inhibit T helper cell function in vivo. In this report, we demonstrate that F(ab')2 anti-L3T4 also permits the induction of immune tolerance in a manner that is independent of T cell depletion. C57BL/6 mice were treated with 1 mg of F(ab')2 anti-L3T4 every other day for 18 days and from the onset were challenged weekly with the immunogen 2C7, a rat mAb to chicken ovalbumin. These mice failed to respond to 2C7 not only during the treatment period but also for at least 5 mo thereafter. This immune tolerance was Ag-specific; the mice rapidly produced antibodies to subsequent challenge with another Ag, human gamma- globulin. Unlike intact anti-L3T4, which immediately depletes L3T4+ cells by greater than 90%, F(ab')2 anti-L3T4 did not initially deplete cells and caused only a partial reduction by the end of the 18-day treatment. This partial reduction of L3T4+ cells did not contribute to the induction of tolerance because mice that were first challenged with 2C7 3 days after stopping the F(ab')2 anti-L3T4 treatment, when L3T4+ cells were lowest, had a normal Ir to 2C7. These findings demonstrate that mAb to L3T4 permits induction of Ag-specific immune tolerance by a mechanism independent of its ability to deplete L3T4+ cells. They also show that F(ab')2 anti-L3T4 treatment does not impair humoral immunity when immunization is initiated after treatment is stopped. Because L3T4 is homologous to CD4 in humans, our findings suggest that F(ab')2 anti- CD4 may offer significant advantages over the use of intact anti-CD4 as an immunosuppressive agent in humans.

This article has been cited by other articles:

				R. Laub, R. Brecht, M. Dorsch, U. Valey, K. Wenk, and F. Emmrich Anti-Human CD4 Induces Peripheral Tolerance in a Human CD4+, Murine CD4-, HLA-DR+ Advanced Transgenic Mouse Model J. Immunol., September 15, 2002; 169(6): 2947 - 2955. [Abstract] [Full Text] [PDF]

				D. J. Herzyk, E. R. Gore, R. Polsky, K. L. Nadwodny, C. C. Maier, S. Liu, T. K. Hart, A. G. Harmsen, and P. J. Bugelski Immunomodulatory Effects of Anti-CD4 Antibody in Host Resistance against Infections and Tumors in Human CD4 Transgenic Mice Infect. Immun., February 1, 2001; 69(2): 1032 - 1043. [Abstract] [Full Text] [PDF]

				P J Bugelskil, D J Herzykl, S Rehm, A G Harmsen, E V Gore, D M Williams, B E Maleeff, A M Badger, A Truneh, S R O'Brien, et al. Preclinical development of keliximab, a PrimatizedTM anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies Human and Experimental Toxicology, April 1, 2000; 19(4): 230 - 243. [Abstract] [PDF]

				M. P. Reddy, C. A. S. Kinney, M. A. Chaikin, A. Payne, J. Fishman-Lobell, P. Tsui, P. R. Dal Monte, M. L. Doyle, M. R. Brigham-Burke, D. Anderson, et al. Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4 J. Immunol., February 15, 2000; 164(4): 1925 - 1933. [Abstract] [Full Text] [PDF]

				F. P. Heinzel and R. M. Rerko Cure of Progressive Murine Leishmaniasis: Interleukin 4 Dominance Is Abolished by Transient CD4+ T Cell Depletion and T Helper Cell Type 1-selective Cytokine Therapy J. Exp. Med., June 21, 1999; 189(12): 1895 - 1906. [Abstract] [Full Text] [PDF]

				G. Cunnane, C. O'Farrelly, C. A. Michie, A. R. McLean, L. W. Moreland, R. P. Bucy, W. J. Koopman, C. L. Mackall, S. M. Steinberg, and R. E. Gress Regeneration of T Cells after Chemotherapy N. Engl. J. Med., June 15, 1995; 332(24): 1650 - 1652. [Full Text]